vialroom

#semaglutide 2024-10-26

Saturday32 messages5 participantstimes are UTC
Highlights from this day
  • VialBot — Testing queue: 7 submissions open, 72 awaiting dispatch. 15:29
  • vialkeeper — STEP 4 had the withdrawal arm, thats the one people quote when they talk about stopping 15:56
  • meniscus_mel — anyone compared their 8 vial dosing against the pen increments 16:18
  • swirl_not_shake — does moving my dose day by two days matter with a seven day half life 18:21
  • VialBot — Purity check: no report on file for lot A-2418. Nothing logged either way. 18:44
VI

steady state is the bit people skip, judging a new dose after eight days tells you almost nothing

MM

how long did the first 40kg take for people at the low doses

[edited]
VI

did anyone hold at 0.25 longer than four weeks before going up

VB

Testing queue: 7 submissions open, 72 awaiting dispatch.

VI

licensed ceiling for weight is 2.4 weekly, anything above that is not a licensed dose

VI

restarted after 6 months off at a low dose and the nausea arrived exactly like the first time

STEP 4 had the withdrawal arm, thats the one people quote when they talk about stopping

14👀8
MM

anyone compared their 8 vial dosing against the pen increments

🙏1⚠️12
MM

im 14 months in at 2.4 and the appetite effect faded, is that a thing

VI

dose day is sunday for me only because thats when i remember, not because sunday matters

SN

the plateau hit me at 20 weeks and moved again about a month later without a dose change

[edited]

mine faded too

went too fast once

plateaus move

held there too

Cited study
Semaglutide vs Liraglutide for Weight Loss in Adults with Overweight or Obesity (STEP 8)
JAMA · 2022
Weekly against daily, head to head.

my 40 vial in 1.5ml gives 8mg/ml so 1 lands on 50 units, thats why i picked that volume

SN

does moving my dose day by two days matter with a seven day half life

🎉10👀18

my plateau was the scale stopping while appetite stayed suppressed, which is a different problem

CF

SELECT was cardiovascular outcomes in people with overweight and existing disease, not a weight trial, thats just me

VB

Purity check: no report on file for lot A-2418. Nothing logged either way.

not the same trial

Cited study
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
New England Journal of Medicine · 2023
Hard cardiovascular endpoints in people with overweight or obesity and established disease.
👀3🧊6